Advocacy Update

Oct. 6, 2023: State Advocacy Update

. 2 MIN READ

Contents

  1. WisMed, WISAM, AMA oppose bill authorizing the sale and marketing of kratom
  2. More articles in this issue
WisMed, WISAM, AMA oppose bill authorizing the sale and marketing of kratom

WisMed, WISAM, AMA oppose bill authorizing the sale and marketing of kratom

It is inappropriate to authorize the sale, marketing or distribution of kratom given that the FDA has not approved any prescription or over-the-counter drug products containing kratom or its two main chemical components, the AMA wrote (PDF) in opposition to Wisconsin Assembly Bill 393 (AB 393). The AMA joined the Wisconsin Medical Society (WisMed) and Wisconsin Society of Addiction Medicine (WISAM) in opposing AB 393.

Haven't subscribed?

Stay current on the latest on the issues impacting physicians, patients and the health care environment with the AMA’s Advocacy Update newsletter.

Sign Up/Create Account

“We have seen an increasing number of deaths associated with kratom the longer that it has been available in the U.S. market,” testified (PDF) WISAM President Ritu Bhatnagar, MD, speaking on behalf of WISAM and WisMed in opposition to AB 393. Dr. Bhatnagar also outlined a wide range of health risks associated with kratom use, including overdose and death.   

“Current research supporting kratom’s medical benefits is insufficient to justify its substantial risk to consumers,” said Dr. Bhatnagar. “There is no evidence that kratom (or its alkaloids) is an appropriate treatment for opioid use disorder.”

Your Powerful Ally

The AMA helps physicians build a better future for medicine, advocating in the courts and on the Hill to remove obstacles to patient care and confront today’s greatest health crises.

Join the AMA

Table of Contents

  1. WisMed, WISAM, AMA oppose bill authorizing the sale and marketing of kratom
  2. More articles in this issue

FEATURED STORIES